

Jacobs Institute of Women's Health

THE GEORGE WASHINGTON UNIVERSITY

MEDICATION ABORTION

Overview of Research & Policy in the United States:
References By Topic Area

Liz Borkowski, MPH

Julia Strasser, MPH

Amy Allina, BA

Susan Wood, PhD

Bridging the Divide:

A Project of the Jacobs Institute of Women's Health

December 2015

I. Background

Medication Abortion Guidelines

- Committee on Practice Bulletins—Gynecology and the Society of Family Planning. (2014). ACOG Practice Bulletin No. 143: Medical Management of First-Trimester Abortion. *Obstetrics & Gynecology*, 123(3), 676–692. <http://doi.org/10.1097/01.AOG.0000444454.67279.7d>
- National Abortion Federation. (2015) 2015 Clinical Policy Guidelines. <http://prochoice.org/education-and-advocacy/2015-clinical-policy-guidelines/>
- Royal College of Obstetricians and Gynaecologists. (2011). The Care of Women Requesting Induced Abortion: Evidence-based Clinical Guideline Number 7. https://www.rcog.org.uk/globalassets/documents/guidelines/abortion-guideline_web_1.pdf
- World Health Organization. (2012). Safe abortion: technical and policy guidelines for health systems, second edition.
- World Health Organization. (2015). Health worker roles in providing safe abortion care and post-abortion contraception.

Medication Abortion Trends; FDA approval of Mifeprex

- CFR - Code of Federal Regulations Title 21. (2015). Retrieved October 23, 2015, from <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8>
- Fitzgerald, A. S., & O'Malley, P. G. (2014). Staying on track when prescribing off-label. *American Family Physician*, 89(1), 4–5.
- Government Accountability Office. Approval and Oversight of the Drug Mifeprex. (2008). Retrieved September 16, 2015, from <http://www.gao.gov/products/GAO-08-751>
- Jones, R. K., & Henshaw, S. K. (2002). Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. *Perspectives on Sexual and Reproductive Health*, 34(3), 154–161.
- Jones, R. K., & Jerman, J. (2014). Abortion Incidence and Service Availability In the United States, 2011. *Perspectives on Sexual and Reproductive Health*, 46(1), 3–14. <http://doi.org/10.1363/46e0414>
- Mifeprex Prescribing Information. (2005). US Food & Drug Administration. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020687s013lbl.pdf
- Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006). Off-label prescribing among office-based physicians. *Archives of Internal Medicine*, 166(9), 1021–1026. <http://doi.org/10.1001/archinte.166.9.1021>

Safety & Efficacy

- Bartz, D., & Goldberg, A. (2009). Medication abortion. *Clinical Obstetrics and Gynecology*, 52(2), 140–150. <http://doi.org/10.1097/GRF.0b013e3181a2b026>
- Beal, M. W. (2007). Update on medication abortion. *Journal of Midwifery & Women's Health*, 52(1), 23–30. <http://doi.org/10.1016/j.jmwh.2006.10.006>
- Committee on Practice Bulletins—Gynecology and the Society of Family Planning. (2014). ACOG Practice Bulletin No. 143: Medical Management of First-Trimester Abortion. *Obstetrics & Gynecology*, 123(3), 676–692. <http://doi.org/10.1097/01.AOG.0000444454.67279.7d>
- Food and Drug Administration. (2011). Mifepristone U.S. Postmarketing Adverse Events Summary through 04/30/2011. Retrieved November 4, 2015, from <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM263353.pdf>
- Government Accountability Office. Approval and Oversight of the Drug Mifeprex. (2008). Retrieved September 16, 2015, from <http://www.gao.gov/products/GAO-08-751>

- Rigterink, E. S., Saftlas, A. F., & Atrash, H. K. (2013). Chapter 16 - Induced Abortion. In M. B. G. T. M. Rexrode (Ed.), *Women and Health (Second Edition)* (pp. 235–250). Academic Press. Retrieved from <http://www.sciencedirect.com/science/article/pii/B9780123849786000169>
- Trussell, J., Nucatola, D., Fjerstad, M., & Lichtenberg, E. S. (2014). Reduction in infection-related mortality since modifications in the regimen of medical abortion. *Contraception*, *89*(3), 193–196. <http://doi.org/10.1016/j.contraception.2013.11.020>

Other Medication Abortion Drugs

- Dodd, J. M., & Crowther, C. A. (2006). Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, *125*(1), 3–8. <http://doi.org/10.1016/j.ejogrb.2005.10.021>
- Hou, S.-P., Fang, A.-H., Chen, Q.-F., Huang, Y.-M., Chen, O.-J., & Cheng, L.-N. (2011). Termination of second-trimester pregnancy by mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate (Rivanol®): a systematic review of Chinese trials. *Contraception*, *84*(3), 214–223. <http://doi.org/10.1016/j.contraception.2011.01.018>
- Lalithkumar, S., Bygdeman, M., & Gemzell-Danielsson, K. (2007). Mid-trimester induced abortion: a review. *Human Reproduction Update*, *13*(1), 37–52. <http://doi.org/10.1093/humupd/dml049>
- Lipp, A. (2008). A review of developments in medical termination of pregnancy. *Journal of Clinical Nursing*, *17*(11), 1411–1418. <http://doi.org/10.1111/j.1365-2702.2007.02204.x>

II. Common Variations from FDA Label

Dosage, time intervals, route of administration, home use of misoprostol

- Chai, J., Wong, C. Y., & Ho, P. C. (2013). A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. *Contraception*, *87*(4), 480–485. <http://doi.org/10.1016/j.contraception.2012.09.022>
- Clark, W., Gold, M., Grossman, D., & Winikoff, B. (2007). Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. *Contraception*, *75*(4), 245–250. [http://doi.org/S0010-7824\(06\)00452-5](http://doi.org/S0010-7824(06)00452-5) [pii]
- Cleland, K., Creinin, M. D., Nucatola, D., Nshom, M., & Trussell, J. (2013). Significant adverse events and outcomes after medical abortion. *Obstetrics and Gynecology*, *121*(1), 166–171. <http://doi.org/10.1097/AOG.0b013e3182755763>
- Cleland, K., & Smith, N. (2015). Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data. *Contraception*, *92*(3), 179–181. <http://doi.org/10.1016/j.contraception.2015.06.016>
- Committee on Practice Bulletins—Gynecology and the Society of Family Planning. (2014). ACOG Practice Bulletin No. 143: Medical Management of First-Trimester Abortion. *Obstetrics & Gynecology*, *123*(3), 676–692. <http://doi.org/10.1097/01.AOG.0000444454.67279.7d>
- Gatter, M., Cleland, K., & Nucatola, D. L. (2015). Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. *Contraception*, *91*(4), 269–273. <http://doi.org/10.1016/j.contraception.2015.01.005>
- Mifeprex Prescribing Information. (2005). US Food & Drug Administration. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020687s013lbl.pdf
- Schaff, E. (2006). Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. *Contraception*, *74*(1), 42–44. [http://doi.org/S0010-7824\(06\)00094-1](http://doi.org/S0010-7824(06)00094-1) [pii]
- Shaw, K. A., Topp, N. J., Shaw, J. G., & Blumenthal, P. D. (2013). Mifepristone-misoprostol dosing interval and effect on induction abortion times: a systematic review. *Obstetrics and Gynecology*, *121*(6), 1335–1347. <http://doi.org/10.1097/AOG.0b013e3182932f37>

- Tang, O.S., & Ho, P.C. (2008). The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. *Contraception*, 74(1), 26-30.
- Wedisinghe, L., & Elsandabesee, D. (2010). Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. *Contraception*, 81(4), 269–274. <http://doi.org/10.1016/j.contraception.2009.09.007>
- Wiegerinck, M. M., Jones, H. E., O’Connell, K., Lichtenberg, E. S., Paul, M., & Westhoff, C. L. (2008). Medical abortion practices: a survey of National Abortion Federation members in the United States. *Contraception*, 78(6), 486–491. <http://doi.org/10.1016/j.contraception.2008.07.015>
- Winikoff, B., Dzuba, I. G., Creinin, M. D., Crowden, W. A., Goldberg, A. B., Gonzales, J., ... Shannon, C. S. (2008). Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. *Obstetrics and Gynecology*, 112(6), 1303–1310. <http://doi.org/10.1097/AOG.0b013e31818d8eb4>

Gestational limits

- Abbas, D., Chong, E., & Raymond, E. G. (2015). Outpatient medical abortion is safe and effective through 70 days gestation. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00256-5](http://doi.org/S0010-7824(15)00256-5) [pii]
- Bracken, H., Dabash, R., Tsertsvadze, G., Posohova, S., Shah, M., Hajri, S., ... Winikoff, B. (2014). A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective comparative open-label trial. *Contraception*, 89(3), 181–186. <http://doi.org/10.1016/j.contraception.2013.10.018>
- Jones, R. K., & Jerman, J. (2014). Abortion Incidence and Service Availability In the United States, 2011. *Perspectives on Sexual and Reproductive Health*, 46(1), 3–14. <http://doi.org/10.1363/46e0414>
- National Abortion Federation. (2015) 2015 Clinical Policy Guidelines. <http://prochoice.org/education-and-advocacy/2015-clinical-policy-guidelines/>
- Royal College of Obstetricians and Gynaecologists. (2011). The Care of Women Requesting Induced Abortion: Evidence-based Clinical Guideline Number 7. https://www.rcog.org.uk/globalassets/documents/guidelines/abortion-guideline_web_1.pdf
- Sanhueza Smith, P., Pena, M., Dzuba, I. G., Garcia Martinez, M. L., Arangure Peraza, A. G., Bousiequez, M., ... Winikoff, B. (2015). Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. *Reproductive Health Matters*, 22(44 Suppl 1), 75–82. [http://doi.org/10.1016/S0968-8080\(15\)43825-X](http://doi.org/10.1016/S0968-8080(15)43825-X)
- Winikoff, B., Dzuba, I. G., Chong, E., Goldberg, A. B., Lichtenberg, E. S., Ball, C., ... Swica, Y. (2012). Extending outpatient medical abortion services through 70 days of gestational age. *Obstetrics and Gynecology*, 120(5), 1070–1076. <http://doi.org/10.1097/AOG.0b013e31826c315f>
- World Health Organization. (2012). Safe abortion: technical and policy guidelines for health systems, second edition.

Non-physician providers

- Barnard, S., Kim, C., Park, M. H., & Ngo, T. D. (2015). Doctors or mid-level providers for abortion. The Cochrane Database of Systematic Reviews, 7, CD011242. <http://doi.org/10.1002/14651858.CD011242.pub2>
- Foster, A. M., Jackson, C. B., LaRoche, K. J., Simmonds, K., & Taylor, D. (2015). From qualified physician to licensed health care professional: the time has come to change mifepristone’s label. *Contraception*, 92(3), 200–202. <http://doi.org/10.1016/j.contraception.2015.06.022>
- Kopp Kallner, H., Gomperts, R., Salomonsson, E., Johansson, M., Marions, L., & Gemzell-Danielsson, K. (2015). The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. *BJOG: An International Journal of Obstetrics and Gynaecology*, 122(4), 510–517. <http://doi.org/10.1111/1471-0528.12982>

- National Abortion Federation. (2015) 2015 Clinical Policy Guidelines. <http://prochoice.org/education-and-advocacy/2015-clinical-policy-guidelines/>
- Ngo, T. D., Park, M. H., & Free, C. (2013). Safety and effectiveness of termination services performed by doctors versus midlevel providers: a systematic review and analysis. *International Journal of Women's Health*, 5, 9–17. <http://doi.org/10.2147/IJWH.S39627>
- Olavarrieta, C. D., Ganatra, B., Sorhaindo, A., Karver, T. S., Seuc, A., Villalobos, A., ... Sanhueza, P. (2015). Nurse versus physician-provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial. *Bulletin of the World Health Organization*, 93(4), 249–258. <http://doi.org/10.2471/BLT.14.143990>
- Renner, R. M., Brahmi, D., & Kapp, N. (2013). Who can provide effective and safe termination of pregnancy care? A systematic review*. *BJOG: An International Journal of Obstetrics and Gynaecology*, 120(1), 23–31. <http://doi.org/10.1111/j.1471-0528.2012.03464.x>
- Samora, J.B. & Leslie, N. (2007). The role of advanced practice clinicians in the availability of abortion services in the United States. *Journal of Obstetric, Gynecologic & Neonatal Nursing* 36(5):471-6. <http://doi.org/10.1111/j.1552-6909.2007.00169.x>
- Taylor, D., Safriet, B., & Weitz, T. (2009). When politics trumps evidence: legislative or regulatory exclusion of abortion from advanced practice clinician scope of practice. *Journal of Midwifery & Women's Health*, 54(1), 4–7. <http://doi.org/10.1016/j.jmwh.2008.09.003>
- Warriner, I. K., Wang, D., Huong, N. T. M., Thapa, K., Tamang, A., Shah, I., ... Meirik, O. (2011). Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. *Lancet* (London, England), 377(9772), 1155–1161. [http://doi.org/10.1016/S0140-6736\(10\)62229-5](http://doi.org/10.1016/S0140-6736(10)62229-5)
- Weitz, T. A., Taylor, D., Desai, S., Upadhyay, U. D., Waldman, J., Battistelli, M. F., & Drey, E. A. (2013). Safety of aspiration abortion performed by nurse practitioners, certified nurse midwives, and physician assistants under a California legal waiver. *American Journal of Public Health*, 103(3), 454–461. <http://doi.org/10.2105/AJPH.2012.301159>
- World Health Organization. (2015). Health worker roles in providing safe abortion care and post-abortion contraception.
- Yarnall, J., Swica, Y., & Winikoff, B. (2009). Non-physician clinicians can safely provide first trimester medical abortion. *Reproductive Health Matters*, 17(33), 61–69.

III. Evolving Evidence for Additional Variations

Home use of mifepristone

- Chong, E., Frye, L. J., Castle, J., Dean, G., Kuehl, L., & Winikoff, B. (2015). A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00277-2](http://doi.org/S0010-7824(15)00277-2) [pii]
- Ngo, T. D., Park, M. H., Shakur, H., & Free, C. (2011). Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. *Bulletin of the World Health Organization*, 89(5), 360–370. <http://doi.org/10.2471/BLT.10.084046>
- Raymond, E. G., Grossman, D., Wiebe, E., & Winikoff, B. (2015). Reaching women where they are: eliminating the initial in-person medical abortion visit. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00258-9](http://doi.org/S0010-7824(15)00258-9) [pii]

Simplifying the first visit

- American College of Obstetricians and Gynecologists. (2011). Ectopic Pregnancy (FAQ155). Retrieved October 28, 2015, from <http://www.acog.org/Patients/FAQs/Ectopic-Pregnancy>

- American College of Obstetricians and Gynecologists. (2013). The Rh Factor: How It Can Affect Your Pregnancy (FAQ027). Retrieved October 28, 2015, from <http://www.acog.org/Patients/FAQs/The-Rh-Factor-How-It-Can-Affect-Your-Pregnancy>
- Bracken, H., Clark, W., Lichtenberg, E. S., Schweikert, S. M., Tanenhaus, J., Barajas, A., Alpert, L., & Winikoff, B. (2011). Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. *BJOG*, 2011, 118, 1, 17-23, *BJOG An International Journal of Obstetrics and Gynaecology*.
- Clark, W., Gold, M., Grossman, D., & Winikoff, B. (2007). Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. *Contraception*, 75(4), 245–250. [http://doi.org/S0010-7824\(06\)00452-5](http://doi.org/S0010-7824(06)00452-5) [pii]
- Clark, W., Panton, T., Hann, L., & Gold, M. (2007). Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. *Contraception*, 75(2), 131–135. <http://doi.org/10.1016/j.contraception.2006.08.001>
- Fielding, S. L., Schaff, E. A., & Nam, N. Y. (2002). Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. *Contraception*, 66(1), 27–31. <http://doi.org/S0010782402003165> [pii]
- Kaneshiro, B., Edelman, A., Sneeringer, R. K., & Ponce de Leon, R. G. (2011). Expanding medical abortion: can medical abortion be effectively provided without the routine use of ultrasound? *Contraception*, 83(3), 194–201. <http://doi.org/10.1016/j.contraception.2010.07.023>
- National Abortion Federation. (2015) 2015 Clinical Policy Guidelines. <http://prochoice.org/education-and-advocacy/2015-clinical-policy-guidelines/>
- Raymond, E. G., & Bracken, H. (2015). Early medical abortion without prior ultrasound. *Contraception* 92, 212-214
- Raymond, E. G., Grossman, D., Wiebe, E., & Winikoff, B. (2015). Reaching women where they are: eliminating the initial in-person medical abortion visit. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00258-9](http://doi.org/S0010-7824(15)00258-9) [pii]
- Schonberg, D., Wang, L. F., Bennett, A. H., Gold, M., & Jackson, E. (2014). The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. *Contraception*, 90(5), 480–487. <http://doi.org/10.1016/j.contraception.2014.07.004>

Simplifying the follow-up visit

- Blum, J., Shochet, T., Lynd, K., Lichtenberg, E. S., Fischer, D., Arnesen, M., ... Blumenthal, P. D. (2012). Can at-home semi-quantitative pregnancy tests serve as a replacement for clinical follow-up of medical abortion? A US study. *Contraception*, 86(6), 757–762. <http://doi.org/10.1016/j.contraception.2012.06.005>
- Chong, E., Frye, L. J., Castle, J., Dean, G., Kuehl, L., & Winikoff, B. (2015). A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00277-2](http://doi.org/S0010-7824(15)00277-2) [pii]
- Clark, W., Bracken, H., Tanenhaus, J., Schweikert, S., Lichtenberg, E. S., & Winikoff, B. (2010). Alternatives to a routine follow-up visit for early medical abortion. *Obstetrics and Gynecology*, 115(2 Pt 1), 264–272. <http://doi.org/10.1097/AOG.0b013e3181c996f3>
- Clark, W., Gold, M., Grossman, D., & Winikoff, B. (2007). Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. *Contraception*, 75(4), 245–250. [http://doi.org/S0010-7824\(06\)00452-5](http://doi.org/S0010-7824(06)00452-5) [pii]
- Clark, W., Panton, T., Hann, L., & Gold, M. (2007). Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. *Contraception*, 75(2), 131–135. <http://doi.org/10.1016/j.contraception.2006.08.001>

- Committee on Practice Bulletins—Gynecology and the Society of Family Planning. (2014). Practice Bulletin No. 143: Medical Management of First-Trimester Abortion. *Obstetrics & Gynecology*, 123(3), 676–692. <http://doi.org/10.1097/01.AOG.0000444454.67279.7d>
- Dunn, S., Panjwani, D., Gupta, M., Meaney, C., Morgan, R., & Feuerstein, E. (2015). Comparison of remote and in-clinic follow-up after methotrexate/misoprostol abortion. *Contraception*, 92(3), 220–226. <http://doi.org/10.1016/j.contraception.2015.05.013>
- Gatter, M., Cleland, K., & Nucatola, D. L. (2015). Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. *Contraception*, 91(4), 269–273. <http://doi.org/10.1016/j.contraception.2015.01.005>
- Godfrey, E. M., Anderson, A., Fielding, S. L., Meyn, L., & Creinin, M. D. (2007). Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. *Contraception*, 75(5), 378–382. [http://doi.org/S0010-7824\(07\)00082-0](http://doi.org/S0010-7824(07)00082-0) [pii]
- Horning, E. L., Chen, B. A., Meyn, L. A., & Creinin, M. D. (2012). Comparison of medical abortion follow-up with serum human chorionic gonadotropin testing and in-office assessment. *Contraception*, 85(4), 402–407. <http://doi.org/10.1016/j.contraception.2011.09.007>
- Li, Y. T., Hou, G. Q., Chen, T. H., Chu, Y. C., Lin, T. C., Kuan, L. C., Lin, M., Huang, S. F., Chen, F. M., Kuo, T. C. (2008). High-dose misoprostol as an alternative therapy after failed medical abortion. *Taiwan. J. Obstet. Gynecol.*, 47(4), 408–411.
- Lynd, K., Blum, J., Ngoc, N. T., Shochet, T., Blumenthal, P. D., & Winikoff, B. (2013). Simplified medical abortion using a semi-quantitative pregnancy test for home-based follow-up. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics*, 121(2), 144–148. <http://doi.org/10.1016/j.ijgo.2012.11.022>
- National Abortion Federation. (2015) 2015 Clinical Policy Guidelines. <http://prochoice.org/education-and-advocacy/2015-clinical-policy-guidelines/>
- Pocius, K. D., Maurer, R., Fortin, J., Goldberg, A. B., & Bartz, D. (2015). Early serum human chorionic gonadotropin (hCG) trends after medication abortion. *Contraception*, 91(6), 503–506. <http://doi.org/10.1016/j.contraception.2015.03.004>
- Reeves, M. F., Kudva, A., Creinin, M. D. (2008) Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. *Contraception*, 78(4), 332–335.
- Winikoff, B., Dzuba, I. G., Creinin, M. D., Crowden, W. A., Goldberg, A. B., Gonzales, J., ... Shannon, C. S. (2008). Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. *Obstetrics and Gynecology*, 112(6), 1303–1310. <http://doi.org/10.1097/AOG.0b013e31818d8eb4>
- World Health Organization. (2012). Safe abortion: technical and policy guidelines for health systems, second edition.

Remote follow-up

- Bracken, H., Lohr, P. A., Taylor, J., Morroni, C., & Winikoff, B. (2014). RU OK? The acceptability and feasibility of remote technologies for follow-up after early medical abortion. *Contraception*, 90(1), 29–35. <http://doi.org/10.1016/j.contraception.2014.03.016>
- Cameron, S. T., Glasier, A., Dewart, H., Johnstone, A., & Burnside, A. (2012). Telephone follow-up and self-performed urine pregnancy testing after early medical abortion: a service evaluation. *Contraception*, 86(1), 67–73. <http://doi.org/10.1016/j.contraception.2011.11.010>
- Grossman, D., & Grindlay, K. (2011). Alternatives to ultrasound for follow-up after medication abortion: a systematic review. *Contraception*, 83(6), 504–510. <http://doi.org/10.1016/j.contraception.2010.08.023>
- Jackson, A. V., Dayananda, I., Fortin, J. M., Fitzmaurice, G., & Goldberg, A. B. (2012). Can women accurately assess the outcome of medical abortion based on symptoms alone? *Contraception*, 85(2), 192–197. <http://doi.org/10.1016/j.contraception.2011.05.019>

- Michie, L., & Cameron, S. T. (2014). Simplified follow-up after early medical abortion: 12-month experience of a telephone call and self-performed low-sensitivity urine pregnancy test. *Contraception*, 89(5), 440–445. <http://doi.org/10.1016/j.contraception.2014.01.010>
- Perriera, L. K., Reeves, M. F., Chen, B. A., Hohmann, H. L., Hayes, J., & Creinin, M. D. (2010). Feasibility of telephone follow-up after medical abortion. *Contraception*, 81(2), 143–149. <http://doi.org/10.1016/j.contraception.2009.08.008>
- Platais, I., Tsereteli, T., Comendant, R., Kurbanbekova, D., & Winikoff, B. (2015). Acceptability and feasibility of phone follow-up with a semiquantitative urine pregnancy test after medical abortion in Moldova and Uzbekistan. *Contraception*, 91(2), 178–183. <http://doi.org/10.1016/j.contraception.2014.11.004>
- Rossi, B., Creinin, M. D., & Meyn, L. A. (2004). Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. *Contraception*, 70(4), 313–317. <http://doi.org/10.1016/j.contraception.2004.04.005>

Self-assessment

- Blum, J., Shochet, T., Lynd, K., Lichtenberg, E. S., Fischer, D., Arnesen, M., ... Blumenthal, P. D. (2012). Can at-home semi-quantitative pregnancy tests serve as a replacement for clinical follow-up of medical abortion? A US study. *Contraception*, 86(6), 757–762. <http://doi.org/10.1016/j.contraception.2012.06.005>
- Cameron, S. T., Glasier, A., Johnstone, A., Dewart, H., & Campbell, A. (2015). Can women determine the success of early medical termination of pregnancy themselves? *Contraception*, 91(1), 6–11. <http://doi.org/10.1016/j.contraception.2014.09.009>
- Hickey, M., & Moore, P. (2015). Follow-up after medical abortion: does simple equal safe? *Lancet (London, England)*, 385(9969), 669–670. [http://doi.org/10.1016/S0140-6736\(14\)61337-4](http://doi.org/10.1016/S0140-6736(14)61337-4)
- Lynd, K., Blum, J., Ngoc, N. T., Shochet, T., Blumenthal, P. D., & Winikoff, B. (2013). Simplified medical abortion using a semi-quantitative pregnancy test for home-based follow-up. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics*, 121(2), 144–148. <http://doi.org/10.1016/j.ijgo.2012.11.022>
- Oppegaard, K. S., Qvigstad, E., Fiala, C., Heikinheimo, O., Benson, L., & Gemzell-Danielsson, K. (2015). Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. *Lancet (London, England)*, 385(9969), 698–704. [http://doi.org/10.1016/S0140-6736\(14\)61054-0](http://doi.org/10.1016/S0140-6736(14)61054-0)
- World Health Organization. (2015). Health worker roles in providing safe abortion care and post-abortion contraception.

Telemedicine

- Gomperts, R., Petow, S. A., Jelinska, K., Steen, L., Gemzell-Danielsson, K., & Kleiverda, G. (2012). Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine. *Acta Obstetrica et Gynecologica Scandinavica*, 91(2), 226–231. <http://doi.org/10.1111/j.1600-0412.2011.01285.x>
- Grindlay, K., Lane, K., & Grossman, D. (2013). Women's and providers' experiences with medical abortion provided through telemedicine: a qualitative study. *Women's Health Issues*, 23(2), e117–22. <http://doi.org/10.1016/j.whi.2012.12.002>
- Grossman, D., Grindlay, K., Buchacker, T., Potter, J. E., & Schmettmann, C. P. (2013). Changes in Service Delivery Patterns After Introduction of Telemedicine Provision of Medical Abortion in Iowa. *American Journal of Public Health*, 103(1), 73–78. <http://doi.org/10.2105/AJPH.2012.301097>
- Grossman, D., Grindlay, K., Buchacker, T., Lane, K., & Blanchard, K. (2011). Effectiveness and acceptability of medical abortion provided through telemedicine. *Obstetrics and Gynecology*, 118(2 Pt 1), 296–303. <http://doi.org/10.1097/AOG.0b013e318224d110>

Guttmacher Institute. (2015b). State Policies in Brief: Medication Abortion. Retrieved from http://www.guttmacher.org/statecenter/spibs/spib_MA.pdf

National Research Council. (2012) The Role of Telehealth in an Evolving Health Care Environment: Workshop Summary. Washington, D.C.: The National Academy Press.

IV. Impact of Restrictions and Potential Policy Changes

Misoprostol-only abortions

- Blum, J., Raghavan, S., Dabash, R., Ngoc, N., Chelli, H., Hajri, S., ... Winikoff, B. (2012). Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics*, 118(2), 166–171. <http://doi.org/10.1016/j.ijgo.2012.03.039>
- Coeytaux, F., Hessini, L., & Allina, A. (2015). Bold Action to Meet Women’s Needs: Putting Abortion Pills in U.S. Women’s Hands. *Women’s Health Issues*, 0(0). <http://doi.org/10.1016/j.whi.2015.08.004>
- Dahiya, K., Ahuja, K., Dhingra, A., Duhan, N., & Nanda, S. (2012). Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion. *Archives of Gynecology and Obstetrics*, 285(4), 1055–1058. <http://doi.org/10.1007/s00404-011-2110-8>
- Grossman, D., White, K., Hopkins, K., & Potter, J. E. (2014). The public health threat of anti-abortion legislation. *Contraception*, 89(2), 73–74. <http://doi.org/10.1016/j.contraception.2013.10.012>
- Grossman, D., Holt, K., Peña, M., Lara, D., Veatch, M., Córdova, D., Gold, M., Winikoff, B., Blanchard, K. (2010). Self-induction of abortion among women in the United States. *Reproductive Health Matters* 18(36):136-146. [http://doi.org/10.1016/S0968-8080\(10\)36534-7](http://doi.org/10.1016/S0968-8080(10)36534-7)
- Jones, R. K. (2011). How commonly do US abortion patients report attempts to self-induce? *American Journal of Obstetrics & Gynecology* 204(1):23.e1-4. <http://doi.org/10.1016/j.ajog.2010.08.019>
- Kulier, R., Kapp, N., Gulmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. The Cochrane Database of Systematic Reviews, (11):CD002855. doi(11), CD002855. <http://doi.org/10.1002/14651858.CD002855.pub4>
- Ngoc, N. T., Blum, J., Raghavan, S., Nga, N. T., Dabash, R., Diop, A., & Winikoff, B. (2011). Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. *Contraception*, 83(5), 410–417. <http://doi.org/10.1016/j.contraception.2010.09.002>
- Winikoff, B., & Sheldon, W. (2012). Use of medicines changing the face of abortion. *International Perspectives on Sexual and Reproductive Health*, 38(3), 164–166. <http://doi.org/3816412> [pii]
- World Health Organization. (2012). Safe abortion: technical and policy guidelines for health systems, second edition.

Current policy issues

- Abbas, D., Chong, E., & Raymond, E. G. (2015). Outpatient medical abortion is safe and effective through 70 days gestation. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00256-5](http://doi.org/S0010-7824(15)00256-5) [pii]
- Arkansas Legislature’s Anti-Choice Bill Spree “Absolutely Devastating” for Women. (2015). Retrieved September 29, 2015, from <http://rhrealitycheck.org/article/2015/04/14/arkansas-legislatures-anti-choice-bill-spree-absolutely-devastating-women/>
- Coeytaux, F., Hessini, L., & Allina, A. (2015). Bold Action to Meet Women’s Needs: Putting Abortion Pills in U.S. Women’s Hands. *Women’s Health Issues*, 0(0). <http://doi.org/10.1016/j.whi.2015.08.004>
- Cleland, K., & Smith, N. (2015). Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data. *Contraception*, 92(3), 179–181. <http://doi.org/10.1016/j.contraception.2015.06.016>

- Espey, E., Leeman, L., Ogburn, T., Skipper, B., Eyman, C., & North, M. (2011). Has mifepristone medical abortion expanded abortion access in New Mexico? A survey of OB-GYN and Family Medicine physicians. *Contraception*, 84(2), 178–183. <http://doi.org/10.1016/j.contraception.2010.11.021>
- Food and Drug Administration. A Brief Overview of Risk Evaluation & Mitigation Strategies (REMS). Retrieved October 28, 2015, from <http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf>
- Foster, A. M., Jackson, C. B., LaRoche, K. J., Simmonds, K., & Taylor, D. (2015). From qualified physician to licensed health care professional: the time has come to change mifepristone’s label. *Contraception*, 92(3), 200–202. <http://doi.org/10.1016/j.contraception.2015.06.022>
- Gold, M., & Chong, E. (2015). If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00249-8](http://doi.org/S0010-7824(15)00249-8) [pii]
- Grossman, D., & Goldstone, P. (2015). Mifepristone by prescription: a dream in the United States but reality in Australia. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00252-8](http://doi.org/S0010-7824(15)00252-8) [pii]
- Grossman, D., White, K., Harris, L., Reeves, M., Blumenthal, P. D., Winikoff, B., & Grimes, D. A. (2015). Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion: a systematic review. *Contraception*, 92(3), 206–211. <http://doi.org/10.1016/j.contraception.2015.06.001>
- Guttmacher Institute. (2015). Laws Affecting Reproductive Health and Rights: State Trends at Midyear, 2015. <http://www.guttmacher.org/media/inthenews/2015/07/01/index.html>
- Guttmacher Institute. (2015). State Policies in Brief: Medication Abortion. http://www.guttmacher.org/statecenter/spibs/spib_MA.pdf
- Leeman, L., Asaria, S., Espey, E., Ogburn, J., Gopman, S., & Barnett, S. (2007). Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion? *Contraception*, 76(2), 96–100. <http://doi.org/10.1016/j.contraception.2007.04.007>
- Louisiana Lawmakers Promise to Propose “Abortion Pill Reversal” Legislation. (2015). Retrieved September 29, 2015, from <http://rhrealitycheck.org/article/2015/07/15/louisiana-lawmakers-promise-propose-abortion-pill-reversal-legislation/>
- Raymond, E. G., Grossman, D., Wiebe, E., & Winikoff, B. (2015). Reaching women where they are: eliminating the initial in-person medical abortion visit. *Contraception*, (Journal Article). [http://doi.org/S0010-7824\(15\)00258-9](http://doi.org/S0010-7824(15)00258-9) [pii]
- Sheldon, W. R., & Winikoff, B. (2015). Mifepristone label laws and trends in use: recent experiences in four US states. *Contraception*, 92(3), 182–185. <http://doi.org/10.1016/j.contraception.2015.06.017>
- The “Science” Behind Arizona’s Mandatory “Abortion Reversal” Advice. (2015). Retrieved September 29, 2015, from <http://rhrealitycheck.org/article/2015/04/08/science-behind-arizonas-mandatory-abortion-reversal-advice/>
- Ventola, C.L. (2009). Off-Label Drug Information: Regulation, Distribution, Evaluation, and Related Controversies. *Pharmacy and Therapeutics*, 34(8), 428 - 440. Retrieved October 28, 2015 from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799128/>